Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

SOUTH SAN FRANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the company's attendance at the 27th Annual JP Morgan Healthcare Conference in San Francisco.

"2008 was an important year for Sunesis, as we have continued to advance the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential to be a first-in-class anti-cancer agent for treating these diseases and potentially other hematologic and solid tumors," said Daniel Swisher, Chief Executive Officer and President of Sunesis. "We completed enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies are enrolling well, with 45 AML patients enrolled in the fourth quarter of 2008 alone. In the first half of 2009, we anticipate reporting additional data from all three of our ongoing voreloxin studies. We remain on track to initiate a pivotal voreloxin study in AML by the end of this year."

Sunesis is providing an update on the progress of its voreloxin clinical trials as follows:

Phase 2 and 1b/2 Studies of Voreloxin in AML

Sunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial, known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented at the 50th Annual Meeting of the American Society of Hematology (ASH) show that voreloxin induces complete remissions in these poor risk patients. At ASH, outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 of vo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 Although RNA-Sequencing is ... first transcriptome-wide analyses appearing around 2008, RNA-Sequencing has ... RNA measurement. In the last several years, assays ... work with smaller input amounts, process degraded RNA, ... samples). On the bioinformatics side, there have been ...
(Date:7/31/2014)... The Kidney Cancer Association (KCA) has established a CNN ... Cancer News. , Bill Bro, KCA CEO, says, “We’re ... an international news organization. When we began using iReport last ... month’s program highlights news of an enzyme that is lost ... study. Kidney Cancer News also presents a report on outcomes ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... and NYSE: SNY) today announced that the Companies intend ... rare pediatric disease priority review voucher in connection with ... priority review voucher entitles the holder to designate a ... 6-month review from the filing date instead of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears are ... Academy of Dermatology (Academy) in an effort to raise ... Bears will host free SPOT me™ skin cancer screenings ... at Soldier Field. SPOT me™ is an educational ... the dangers and risks of skin cancer, and encourages ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.511 04/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram negative, , ...
... Multiporator / Electroporator 2510 , , , , , , , ... Protocol No. 4308 915.509 12/2001 , , , ... , Microorganism , Clostridium ... type , Bacteria, gram positive, , ...
... Multiporator , , , , , , , , ... Protocol No. 4308 915.031 12/1999 , , , , , ... , Cell line , CHO, Chinese hamster ... with , Rat-DPP IV (in bidistilled H 2 O), stable transfection, , ...
Cached Biology Technology:Escherichia coli C600 2Escherichia coli C600 3Clostridium botulinum 2CHO 2
(Date:7/31/2014)... and beige adipocytes, or fat cells, are inherently different. ... each plays its own role in metabolism. In the ... most prevalent. Its primary function is energy storage. On ... generate heat but are only found in a few ... represent a special type of brown adipocytes, appear mixed ...
(Date:7/31/2014)... have shown that marine noise can affect animal movement ... Universities of Bristol and Exeter and the cole Pratique ... that boat noise stops embryonic development and increases larval ... sea slug Stylocheilus striatus used in this ... and later feed on toxic alga but this study, ...
(Date:7/30/2014)... uses reversible epigenetic processes to regulate its genes, and ... a picture of the genome regulation taking place in ... Genome Biology and illustrates how the truffle ... genes,. The authors say this may shed light on ... Black truffles (Tuber melanosporum), also known as Prigord truffles, ...
Breaking Biology News(10 mins):Hope for the overweight 2Boat noise impacts development and survival of sea hares 2How black truffles deal with the jumpers in their genome 2
... 2013 Taking a page from Chinese herbal medicine, ... today initiated the first-in-human clinical trial for pancreatic cancer ... as "Thunder God vine." The first patient ... at Scottsdale Healthcare,s Virginia G. Piper Cancer Center Clinical ...
... NY -- In plants, the growth of organs such ... of meristems. These reservoir-like compartments hold stem cells, which ... types. At Cold Spring Harbor Laboratory ... plants to obtain insights about how plants regulate their ...
... predicted that tree species will respond to global warming ... a new study of 65 different species in 31 ... Nearly 80 percent of the species aren,t yet ... staying in place -- but speeding up their life ...
Cached Biology News:TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 2TGen and Scottsdale Healthcare launch Phase I 'Thunder God vine' trial for cancer 3In odd-looking mutant, clues about how maize plants control stem cell number 2Climate change may speed up forests' life cycles 2
GOAT ANTI HUMAN FACTOR 8RELATED ANTIGEN...
ANTI CORTIS BIN GLOB...
... Johnstone and M.W. Turner ... describes step-by-step methods for ... relevant molecules, the use ... specific analytical probes and ...
Request Info...
Biology Products: